HELP

MKT CAP:$277M

Cybin Inc. Common Stock

Market Cap

$277M

Healthcare·Biotechnology·🇨🇦 Canada·NASDAQ

Healthcare·Biotechnology·🇨🇦·NASDAQ

Stock Price

$5.75-$2.53 (-30.56%)

Apr 23, 2026

Company Details

Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder

CEO

Michael F. Cola

IPO Date

Sep 13, 2019

Website

www.cybin.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$120M

EPS (Diluted)

-$5.17

Free Cash Flow

-$117M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q3 2026

Dec 31, 2025

$0EPS -$1.77

Q2 2026

Oct 29, 2025

$0EPS -$1.94

FY 2025

Jun 30, 2025

$0EPS -$0.45

Q4 2025

Jun 30, 2025

$0EPS -$1.07

Q3 2025

Feb 10, 2025

$0EPS -$0.39

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 22	$0	$0	-$12M
Q4 22	$0	$0	-$12M
Q1 23	$0	$0	-$10M
Q2 23	$0	$0	-$9M
Q3 23	$0	$0	-$9M
Q4 23	$0	$0	-$10M
Q1 24	$0	$0	-$9M
Q2 24	$0	$0	-$10M
Q3 24	$0	$0	-$20M
Q4 24	$0	$0	-$18M
Q1 25	$0	$0	-$11M
Q2 25	$0	$0	-$42M
Q3 25	$0	$0	-$24M
Q4 25	$0	$0	-$24M
Q2 26	$0	$0	-$40M
Q3 26	$0	$0	-$41M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 22	-$9M	-$9M
Q4 22	-$7M	-$7M
Q1 23	-$8M	-$8M
Q2 23	-$11M	-$13M
Q3 23	-$8M	-$8M
Q4 23	-$8M	-$8M
Q1 24	-$8M	-$8M
Q2 24	-$8M	-$9M
Q3 24	-$19M	-$19M
Q4 24	-$15M	-$15M
Q1 25	-$15M	-$15M
Q2 25	-$19M	-$19M
Q3 25	-$20M	-$20M
Q4 25	-$15M	-$16M
Q2 26	-$48M	-$49M
Q3 26	-$32M	-$32M

Capital Expenditures

Quarter	CapEx
Q3 22	$121.3K
Q4 22	$88.4K
Q1 23	$152.0K
Q2 23	$2M
Q3 23	$151.3K
Q4 23	$159.3K
Q1 24	$47.5K
Q2 24	$188.5K
Q3 24	$125.7K
Q4 24	$157.1K
Q1 25	$126.4K
Q2 25	$248.9K
Q3 25	$228.1K
Q4 25	$792.2K
Q2 26	$608.1K
Q3 26	$384.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 22	—	+44.6%
Q4 22	—	+26.9%
Q1 23	—	-3.9%
Q2 23	—	-27.9%
Q3 23	—	-26.5%
Q4 23	—	-16.1%
Q1 24	—	-5.1%
Q2 24	—	+12.8%
Q3 24	—	+123.5%
Q4 24	—	+83.9%
Q1 25	—	+16.9%
Q2 25	—	+316.6%
Q3 25	—	+19.1%
Q4 25	—	+32.1%
Q2 26	—	+271.4%
Q3 26	—	-2.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 22	$3M	—
Q4 22	$2M	—
Q1 23	$2M	—
Q2 23	$783.4K	—
Q3 23	$714.7K	—
Q4 23	$351.5K	—
Q1 24	$931.7K	—
Q2 24	$1M	—
Q3 24	$7M	—
Q4 24	$927.4K	—
Q1 25	$2M	—
Q2 25	$24M	—
Q3 25	$3M	—
Q4 25	$2M	—
Q2 26	$525.8K	—
Q3 26	$4M	—

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q3 22	$4M	$8M	$291.6K
Q4 22	$4M	$7M	$228.0K
Q1 23	$5M	$5M	$521.0K
Q2 23	$4M	$5M	$65.8K
Q3 23	$5M	$4M	$48.2K
Q4 23	$6M	$4M	$8.8K
Q1 24	$5M	$4M	$8.8K
Q2 24	$5M	$5M	$11.0K
Q3 24	$6M	$14M	$16.8K
Q4 24	$9M	$8M	$1M
Q1 25	$4M	$7M	$22.7K
Q2 25	$7M	$35M	$671.4K
Q3 25	$14M	$9M	$457.2K
Q4 25	$14M	$8M	$2M
Q2 26	$26M	$14M	$486.8K
Q3 26	$24M	$16M	$1M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$39M	$0	$39M
Q1 23	$31M	$190.0K	$31M
Q2 23	$22M	$203.2K	$22M
Q3 23	$16M	$91.3K	$17M
Q4 23	$12M	$0	$12M
Q1 24	$7M	$0	$7M
Q2 24	$13M	$0	$13M
Q3 24	$28M	$0	$28M
Q4 24	$153M	$0	$153M
Q1 25	$134M	$0	$134M
Q2 25	$113M	$0	$113M
Q3 25	$100M	$0	$100M
Q4 25	$99M	$0	$99M
Q1 26	$87M	$0	$87M
Q2 26	$117M	$0	$117M
Q3 26	$196M	$0	$196M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 22	5M	+3.6%	+55.9%
Q4 22	5M	+1.2%	+15.5%
Q1 23	5M	+1.2%	+11.5%
Q2 23	5M	+2.8%	+9.1%
Q3 23	5M	+4.5%	+9.9%
Q4 23	5M	+3.8%	+12.8%
Q1 24	5M	+5.1%	+17.2%
Q2 24	6M	+13.8%	+29.7%
Q3 24	9M	+42.2%	+76.7%
Q4 24	20M	+127.8%	+287.5%
Q1 25	20M	-2.1%	+261.0%
Q2 25	20M	+2.1%	+224.0%
Q3 25	20M	0.0%	+127.8%
Q4 25	21M	+4.5%	+4.5%
Q2 26	24M	+15.8%	+23.6%
Q3 26	24M	0.0%	+21.0%

Shares Outstanding